Healthcare [ 7/13 ] | Biotechnology [ 82/163 ]
NASDAQ | Common Stock
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors.
The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy.
Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 29, 24 | -0.40 Increased by +13.37% | -0.49 Increased by +18.67% |
| Mar 12, 24 | -0.56 Decreased by -1.82% | -0.41 Decreased by -36.59% |
| Nov 9, 23 | -0.48 Increased by +11.11% | -0.52 Increased by +7.69% |
| Aug 9, 23 | -0.48 Decreased by -4.35% | -0.49 Increased by +2.04% |
| May 11, 23 | -0.46 Decreased by -4.55% | -0.54 Increased by +14.81% |
| Mar 15, 23 | -0.55 Increased by +78.09% | -0.52 Decreased by -5.77% |
| Nov 10, 22 | -0.54 Decreased by -116.00% | -0.51 Decreased by -5.88% |
| Aug 11, 22 | -0.46 Increased by +98.39% | -0.46 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -19.71 M Decreased by -29.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 2.06 M Increased by +N/A% | -22.13 M Increased by +47.07% | Decreased by -1.08 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -18.51 M Decreased by -17.56% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -18.30 M Decreased by -39.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -15.16 M Decreased by -17.89% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -41.81 M Decreased by -259.36% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -15.75 M Decreased by -78.17% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -13.12 M Decreased by -48.22% | Decreased by N/A% Decreased by N/A% |